Takeda(US:TAK)2025-10-30 10:00Financial Performance - FY2025 H1 revenue decreased by 69% to JPY 22195 billion[21], a 39% decrease at CER[21] - FY2025 H1 core operating profit decreased by 112% to JPY 6392 billion[21], an 88% decrease at CER[21] - FY2025 H1 adjusted free cash flow increased by 1123% to JPY 5254 billion[21] - Growth & Launch Products increased by 53% at CER in H1[18, 24] - The company maintains broadly flat revenue guidance at CER[18, 36] Pipeline Update - Rusfertide and oveporexton are on track to file within FY2025[18] - Zasocitinib Ph3 psoriasis data is expected in H2[18] - Mezagitamab Ph1b IgAN data show durable eGFR over 18 months[18] - A partnership with Innovent Biologics to bolster the oncology pipeline[18] Oncology Partnership - Takeda entered into a license and collaboration agreement with Innovent Biologics for rights to IBI343 and IBI363, and an exclusive option to license rights to IBI3001, in each case worldwide outside of mainland China, Hong Kong, Macau and Taiwan[12] - IBI363 has demonstrated encouraging data across multiple solid tumor types, with a confirmed objective response rate (cORR) of 367% in sqNSCLC (IO-Refractory) and a median overall survival (mOS) of 153 months at 1/15 mg/kg[80] - IBI343 has shown robust monotherapy activity and a favorable safety profile, with a cORR of ~30% in 2L Pancreatic Cancer (CLDN182 1+/2+/3+ ≥60% expression) and an mOS of 121 months[94]